NASDAQ:NEONeoGenomics Stock Price, Forecast & News

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NEO stock has increased by 6.0% and is now trading at $26.26. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NeoGenomics.

NeoGenomics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for NeoGenomics.

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings data on Tuesday, April, 28th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.04. The medical research company had revenue of $106.03 million for the quarter, compared to the consensus estimate of $106.03 million. NeoGenomics had a net margin of 0.82% and a return on equity of 2.94%. The company's revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.03) EPS. View NeoGenomics' earnings history.

NeoGenomics updated its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $106-106 million, compared to the consensus revenue estimate of $104.42 million.

9 analysts have issued 1-year price objectives for NeoGenomics' stock. Their forecasts range from $9.00 to $38.00. On average, they anticipate NeoGenomics' stock price to reach $30.63 in the next year. This suggests a possible upside of 16.6% from the stock's current price. View analysts' price targets for NeoGenomics.

Press coverage about NEO stock has been trending very negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. NeoGenomics earned a news impact score of -3.5 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutNeoGenomics.

Some companies that are related to NeoGenomics include DiaSorin (DSRLF), DENTSPLY SIRONA (XRAY), Sartorius (SRT), BIO-TECHNE (TECH), ABIOMED (ABMD), argenx (ARGX), Qiagen (QGEN), Davita (DVA), PPD (PPD), Horizon Therapeutics (HZNP), Bausch Health Companies (BHC), Icon (ICLR), Mylan (MYL), Universal Health Services (UHS) and Charles River Laboratories Intl. (CRL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Square (SQ), Cisco Systems (CSCO), Inseego (INSG), Advanced Micro Devices (AMD) and Crispr Therapeutics (CRSP).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.57%), Invesco Ltd. (3.67%), State Street Corp (2.86%), Janus Henderson Group PLC (2.65%), Eagle Asset Management Inc. (2.38%) and Geode Capital Management LLC (1.43%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View institutional ownership trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Granahan Investment Management Inc. MA, Ranger Investment Management L.P., BlackRock Inc., Cowen Prime Services LLC, Emerald Mutual Fund Advisers Trust, Russell Investments Group Ltd., and Emerald Advisers LLC. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones, and William Bonello. View insider buying and selling activity for NeoGenomics.

NEO stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Fred Alger Management LLC, Federated Hermes Inc., State Street Corp, Eaton Vance Management, Wells Fargo & Company MN, TCW Group Inc., and Deutsche Bank AG. View insider buying and selling activity for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $26.26.

NeoGenomics has a market capitalization of $2.77 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis. NeoGenomics employs 1,700 workers across the globe.

The official website for NeoGenomics is www.neogenomics.com.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]